CYP 2.44% 20.0¢ cynata therapeutics limited

riken temcell, page-24

  1. 1,070 Posts.
    lightbulb Created with Sketch. 546
    With further research of RIKEN's stem cells:

    1.  The recent monkey-to-monkey trials did not use their "allogeneic iPSC-retinal pigment epithelial cells". And they plan to use these allogeneic cells in their next trial.

    2. Major concerns about potential immunogenecity (immune rejection) of their type of stem cells have been raised by their peers.
    (http://stemcellassays.com/2015/09/first-ips-cell-clinical-trial-insights/)


    Either way, RIKEN in their next clinical trial with the use of their "allogeneic stem cells" are also in a fight to prove whether their iPS cell bank are truly useful/valid or not.
    http://www.riken.jp/en/pr/press/2016/20160916_2/
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
20.0¢
Change
-0.005(2.44%)
Mkt cap ! $36.11M
Open High Low Value Volume
20.5¢ 21.5¢ 20.0¢ $13.43K 65.55K

Buyers (Bids)

No. Vol. Price($)
3 109917 20.0¢
 

Sellers (Offers)

Price($) Vol. No.
25.0¢ 9225 2
View Market Depth
Last trade - 16.10pm 15/08/2024 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.